TriangleNCT00738530 · OUTCOME
Percentage of Participants Who Died
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline up to 4.25 years
Analysis population: ITT population included all participants randomized into the study.
Groups in this outcome
Bevacizumab + IFN-Alfa-2A
Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
Placebo + IFN-Alfa-2A
Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
| Group | Source count |
|---|---|
| Bevacizumab + IFN-Alfa-2A | 327 |
| Placebo + IFN-Alfa-2A | 322 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bevacizumab + IFN-Alfa-2A | 67.3 | Not reported | Not reported | Not reported | Not reported |
| Placebo + IFN-Alfa-2A | 69.6 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 67.3
- group Id
- OG001
- value
- 69.6
- denoms
- counts
- group Id
- OG000
- value
- 327
- group Id
- OG001
- value
- 322
- units
- Participants
- groups
- description
- Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
- id
- OG000
- title
- Bevacizumab + IFN-Alfa-2A
- description
- Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
- id
- OG001
- title
- Placebo + IFN-Alfa-2A
- param Type
- NUMBER
- population Description
- ITT population included all participants randomized into the study.
- reporting Status
- POSTED
- time Frame
- Baseline up to 4.25 years
- title
- Percentage of Participants Who Died
- type
- PRIMARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice